{"id":"NCT00723190","sponsor":"Shionogi","briefTitle":"Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","officialTitle":"An Open-Label, Chronic Exposure Evaluation of the Safety of CLONICEL (Clonidine HCl Sustained Release) in the Treatment of Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2010-03","completion":"2010-06","firstPosted":"2008-07-28","resultsPosted":"2012-02-27","lastUpdate":"2018-04-18"},"enrollment":303,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"CLONICEL (Clonidine HCl sustained release)","otherNames":[]}],"arms":[{"label":"Arm A","type":"EXPERIMENTAL"}],"summary":"The purpose of this 12-month, multi-center, open-label study is to evaluate the safety of CLONICEL (clonidine HCl sustained release) when administered chronically under regular clinical conditions either as monotherapy or in combination with stimulant therapy to children and adolescents with attention deficit hyperactivity disorder (ADHD).","primaryOutcome":{"measure":"Safety Assessment in Terms of Adverse Events (Treatment-emergent [TEAEs] and Serious [SAEs])","timeFrame":"1 year","effectByArm":[{"arm":"KAPVAY (CLONICEL)","deltaMin":301,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":27,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":301},"commonTop":["Somnolence","Headache","Upper Respiratory Tract Infection","Abdominal Pain Upper","Fatigue"]}}